Targeting the transforming growth factor-β signaling pathway in human cancer

Derynck R, Miyazono K. TGF-beta and the TGF-beta Family. In: Derynck R, Miyazono K . editors, The TGF-beta Family. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 2008. p. 29-43

10.1038/ncb434

10.1016/j.cell.2008.07.001

10.1101/gad.1636908

10.1242/jcs.00229

10.1038/nrm2262

10.1126/science.8388127

Grady WM, Markowitz SD. TGF-beta signaling pathway and tumor suppression. In: Derynck R, Miyazono K. editors, The TGF-beta Family. Cold Spring Harbor Laboratory Press; New York; 2008. p. 889-964

10.1093/emboj/20.3.480

10.1016/S0092-8674(03)00432-X

10.1038/sj.onc.1208475

10.1002/jcp.10066

10.1038/cr.2008.316

10.1016/j.ccr.2007.08.020

10.1073/pnas.98.3.992

10.1016/j.febslet.2006.04.033

Datta PK, Mann JR. Transforming growth factor-beta (TGF-beta) signaling inhibitors in cancer therapy. In: Jakowlew SB. editor, Tranforming growth factor-beta in cancer therapy. Human press; Totowa, NJ: 2008. p. 573-87

Pardali K, 2007, Biochim Biophys Acta, 1775, 21

10.1016/j.bbadis.2008.01.006

10.1002/(SICI)1097-0215(19990702)82:1<43::AID-IJC9>3.0.CO;2-0

10.1016/S1286-4579(99)00251-8

10.1002/ijc.1381

Chen T, 2001, Cancer Res, 61, 4679

Myeroff LL, 1995, Cancer Res, 55, 5545

10.1146/annurev.biochem.67.1.753

10.1038/cr.2008.325

10.1101/gad.1350705

10.1074/jbc.273.52.34671

10.1128/MCB.20.9.3157-3167.2000

10.1038/ncb807

10.1016/S0092-8674(00)81132-0

10.1158/0008-5472.CAN-05-0800

10.1016/j.canlet.2006.05.008

10.1016/j.yexcr.2005.03.009

10.1073/pnas.0508977103

10.1038/nature02006

10.1242/jcs.02554

Zhang YE. Non-Smad TGF-beta signaling pathways. In: Derynck R, Miyazono K, editors, The TGF-beta Family. Cold Spring Harbor Laboratory Press: New York; 2008. p. 419-38

10.1091/mbc.12.1.27

10.1074/jbc.M309131200

10.1128/MCB.24.5.2169-2180.2004

10.1038/ncb1117

10.1073/pnas.0402048101

10.1016/0092-8674(87)90146-2

10.1038/nrc1926

10.1126/science.1090922

Muraoka-Cook RS, 2005, Clin Cancer Res, 11, 937s, 10.1158/1078-0432.937s.11.2

10.1016/j.cardiores.2004.10.036

10.1016/j.ceb.2003.10.006

10.1172/JCI200320530

10.1371/journal.pone.0004355

10.1053/j.gastro.2008.04.038

10.1091/mbc.E04-08-0658

10.1016/j.cell.2008.03.027

10.1128/MCB.24.10.4241-4254.2004

10.1091/mbc.11.1.51

10.1074/jbc.M201178200

10.1038/sj.onc.1207856

10.1172/JCI30740

10.1158/0008-5472.CAN-06-3381

10.1016/j.ccr.2007.12.004

10.1158/0008-5472.CAN-07-5597

Akhurst RJ. TGF-beta signaling in epithelial-mesenchymal transition and invasion and metastasis. In: Derynck R, Miyazono K. editors, The TGF-beta Family. Cold Spring Harbor Laboratory Press; New York: 2008. p. 931-64

10.1128/MCB.22.23.8184-8198.2002

Aguilera A, 2005, Curr Opin Investig Drugs, 6, 262

10.1038/sj.gt.3302436

10.1158/0008-5472.CAN-05-2328

Dvorchik BH, 2000, Curr Opin Mol Ther, 2, 253

Arteaga CL, McPherson JM. Development of TGF-beta based therapeutic agents: capitalizing on TGF-beta's mechanisms of action and signal transduction pathways. In: Derynck R, Miyazono K. editors, The TGF-beta Family. Cold Spring Harbor Laboratory Press; New York: 2008. p. 1023-62

10.1089/oli.2006.0053

10.2174/156800906778742460

10.1038/sj.cgt.7700922

10.1053/j.seminoncol.2004.07.022

10.2174/1568011043352713

Christiansen J, 2004, Mol Cancer Ther, 3, 1493, 10.1158/1535-7163.1493.3.11

Cordeiro MF, 2003, Curr Opin Mol Ther, 5, 199

Rowland-Goldsmith MA, 2002, Mol Cancer Ther, 1, 161

10.1172/JCI0215234

10.1038/sj.onc.1205439

Muraoka-Cook RS, 2005, Clin Cancer Res, 11, 937s, 10.1158/1078-0432.937s.11.2

Ananth S, 1999, Cancer Res, 59, 2210

10.1161/CIRCULATIONAHA.104.528695

10.1038/nrd1580

10.2174/1568011043352830

Hjelmeland MD, 2004, Mol Cancer Ther, 3, 737, 10.1158/1535-7163.737.3.6

10.1158/0008-5472.CAN-04-0018

10.1158/0008-5472.CAN-04-1013

10.1215/15228517-2007-010

10.1016/j.tcb.2004.01.001

Ilaria RL, 2007, J Clin Oncol, 25, 2515, 10.1200/jco.2007.25.18_suppl.2515

10.1111/j.1349-7006.2005.00103.x

10.1038/sj.ki.5001775

Lacher MD, Korn WM, Akhurst RJ. Reversal of EMT by small molecule inhibitors of TGF-beta type I and II receptors: Implications for carcinoma treatment. In: Jakowlew SB. editor, Tranforming growth factor-beta in cancer therapy. Human press: Totowa, NJ; 2008. p. 707-22

Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009;277(1):114-20

10.1158/1535-7163.MCT-07-0337

Singh J, 2005, Chem Today, 23, 35

Jinnin M, 2006, Mol Pharmacol, 69, 597, 10.1124/mol.105.017483

Calvo-Aller E, 2008, J Clin Oncol, 26, 14554, 10.1200/jco.2008.26.15_suppl.14554

10.1074/jbc.M306248200

10.1038/sj.onc.1208964

10.1101/gad.13.7.804

10.1016/j.molcel.2004.06.007

10.1038/nature07086

10.1073/pnas.0506517102

10.1158/0008-5472.CAN-06-3950

10.1038/sj.onc.1202642

Losi L, 2007, Oncol Rep, 17, 1095

10.1053/j.gastro.2008.03.003

10.1007/978-3-540-71279-4_16

10.1517/13543784.14.6.629

10.1167/iovs.02-0978

10.1097/01.ASN.0000074238.61967.B7

10.1158/0008-5472.CAN-06-0068

10.1021/jm0205705

10.1111/j.1349-7006.2006.00357.x

10.1158/0008-5472.CAN-06-2389

10.1016/S1535-6108(03)00135-1

10.1038/sj.onc.1208556

Bandyopadhyay A, 1999, Cancer Res, 59, 5041